Seladelpar - (IDEAL)

November 4, 2026: Gilead Sciences (NASDAQ: GILD) reported detailed Phase 3 IDEAL results for Livdelzi (seladelpar) in adults with primary biliary cholangitis (PBC) whose alkaline phosphatase (ALP) was above normal but below 1.67× ULN despite UDCA, or who were intolerant to UDCA. At Week 52, 75.4% (49/65) of Livdelzi-treated participants achieved the ALP normalization composite endpoint (ALP ≤1.0× ULN plus ≥15% decrease from baseline) versus 16.1% (5/31) on placebo. Response was seen by Month 1 (52.3% vs 6.5%) and was sustained through Week 52.

IDEAL was a randomized, double-blind, placebo-controlled trial (NCT06060665) in 96 adults. Safety was consistent with prior Livdelzi studies, with no new safety concerns; serious adverse events occurred in 3.1% of the Livdelzi group and 12.9% of placebo, with none deemed related to study drug.

The data will be presented at The Liver Meeting 2026 (AASLD), November 5-9, 2026, in Denver, and were accepted for publication in the Journal of Hepatology. Gilead said it will engage global regulatory authorities based on these results.